| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Institute for Pathology, University of Basel, CH-4003 Basel, Switzerland [P. S., H. M., H. B., A. N., M. J. M., G. S.], and Laboratory for Cancer Genetics, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892-4470 [J. K., L. B., O-P. K.]
Gene amplifications are common in many different tumor types and may confer diagnostic, prognostic, or therapeutic information for patient management. Tedious experiments are often required to determine which tumor types have amplifications of a specific oncogene. To facilitate rapid screening for molecular alterations in many different malignancies, a tissue microarray consisting of samples from 17 different tumor types was generated. Altogether, 397 individual tumors were arrayed in a single paraffin block. To determine whether results from the literature can be reproduced on minute tissue samples (diameter, 0.6 mm), amplification of three extensively studied oncogenes (CCND1, CMYC, and ERBB2) was analyzed in three fluorescence in situ hybridization experiments from consecutive sections cut from the tissue microarray. Amplification of CCND1 was found in breast, lung, head and neck, and bladder cancer, as well as in melanoma. ERBB2 was amplified in bladder, breast, colon, stomach, testis, and lung cancer. CMYC was amplified in breast, colon, kidney, lung, ovary, bladder, head and neck, and endometrial cancer. These results confirm and even extend existing data in the literature on such amplifications. In summary, we applied three fluorescence in situ hybridization experiments to analyze amplifications of three oncogenes in three x 397 tumors within a week. This demonstrates the power of using minute arrayed tissue specimens for tumor screening.
This article has been cited by other articles:
![]() |
S.-M. SHEEN-CHEN, H. ZHANG, C.-C. HUANG, and R.-P. TANG Insulin-like Growth Factor-binding Protein-3 in Breast Cancer: Analysis with Tissue Microarray Anticancer Res, April 1, 2009; 29(4): 1131 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. RAWNAQ, H. KLEINHANS, M. UTO, P. G. SCHURR, U. REICHELT, G. CATALDEGIRMEN, K. A. GAWAD, E. F. YEKEBAS, M. SCHACHNER, J. R. IZBICKI, et al. Subset of Esophageal Adenocarcinoma Expresses Adhesion Molecule L1 in Contrast to Squamous Cell Carcinoma Anticancer Res, April 1, 2009; 29(4): 1195 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ruano, T. Ribalta, A. R. de Lope, Y. Campos-Martin, C. Fiano, E. Perez-Magan, J.-L. Hernandez-Moneo, M. Mollejo, and B. Melendez Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration Am J Clin Pathol, February 1, 2009; 131(2): 257 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. SCHMIDT, S. BIESTERFELD, A. KUMMEL, A. FALDUM, M. SEBASTIAN, C. TAUBE, R. BUHL, and R. WIEWRODT Tissue Microarrays are Reliable Tools for the Clinicopathological Characterization of Lung Cancer Tissue Anticancer Res, January 1, 2009; 29(1): 201 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-M. Sheen-Chen, C.-C. Huang, R.-P. Tang, F.-F. Chou, and H.-L. Eng Prognostic Value of Signal Transducers and Activators of Transcription 3 in Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2286 - 2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Opitz, A. Soltermann, M. Abaecherli, M. Hinterberger, N. Probst-Hensch, R. Stahel, H. Moch, and W. Weder PTEN expression is a strong predictor of survival in mesothelioma patients Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 502 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Al-Kuraya, H. Novotny, P. Bavi, A. K Siraj, S. Uddin, A. Ezzat, N. A. Sanea, F. Al-Dayel, H. Al-Mana, S. S Sheikh, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer J. Clin. Pathol., July 1, 2007; 60(7): 768 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Helguera, J. A. Rodriguez, and M. L. Penichet Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Thodou, G Kontogeorgos, D Theodossiou, and M Pateraki Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J. Clin. Pathol., March 1, 2006; 59(3): 274 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Berger, D. W. Davis, C. Tellez, V. G. Prieto, J. E. Gershenwald, M. M. Johnson, D. L. Rimm, and M. Bar-Eli Automated Quantitative Analysis of Activator Protein-2{alpha} Subcellular Expression in Melanoma Tissue Microarrays Correlates with Survival Prediction Cancer Res., December 1, 2005; 65(23): 11185 - 11192. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gilbertson ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty Oncologist, August 1, 2005; 10(7): 508 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Maggio-Price, H. Bielefeldt-Ohmann, P. Treuting, B. M. Iritani, W. Zeng, A. Nicks, M. Tsang, D. Shows, P. Morrissey, and J. L. Viney Dual Infection with Helicobacter bilis and Helicobacter hepaticus in P-Glycoprotein-Deficient mdr1a-/- Mice Results in Colitis that Progresses to Dysplasia Am. J. Pathol., June 1, 2005; 166(6): 1793 - 1806. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells Cancer Res., May 15, 2005; 65(10): 4253 - 4260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.C. Reshmi and S.M. Gollin Chromosomal Instability in Oral Cancer Cells Journal of Dental Research, February 1, 2005; 84(2): 107 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nambiar, A. Mirmohammadsadegh, R. Doroudi, A. Gustrau, A. Marini, G. Roeder, T. Ruzicka, and U. R. Hengge Signaling Networks in Cutaneous Melanoma Metastasis Identified by Complementary DNA Microarrays Arch Dermatol, February 1, 2005; 141(2): 165 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Nielsen, F. D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma Clin. Cancer Res., August 15, 2004; 10(16): 5367 - 5374. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zheng, R. Simon, M. Mirlacher, R. Maurer, T. Gasser, T. Forster, P. A. Diener, M. J. Mihatsch, G. Sauter, and P. Schraml TRIO Amplification and Abundant mRNA Expression Is Associated with Invasive Tumor Growth and Rapid Tumor Cell Proliferation in Urinary Bladder Cancer Am. J. Pathol., July 1, 2004; 165(1): 63 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Srivastava, L. Bubendorf, M. Raffeld, C. Bucher, J. Torhorst, G. Sauter, C. Olsen, O. P. Kallioniemi, O. Eidelman, and H. B. Pollard Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients Clin. Cancer Res., April 1, 2004; 10(7): 2344 - 2350. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Grushko, J. J. Dignam, S. Das, A. M. Blackwood, C. M. Perou, K. K. Ridderstrale, K. N. Anderson, M.-J. Wei, A. J. Adams, F. G. Hagos, et al. MYC Is Amplified in BRCA1-Associated Breast Cancers Clin. Cancer Res., January 15, 2004; 10(2): 499 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Simon, S. Panussis, R. Maurer, H. Spichtin, K. Glatz, C. Tapia, M. Mirlacher, A. Rufle, J. Torhorst, and G. Sauter KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations Clin. Cancer Res., January 1, 2004; 10(1): 178 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Tzankov, A-C Pehrs, A Zimpfer, S Ascani, A Lugli, S Pileri, and S Dirnhofer Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases J. Clin. Pathol., October 1, 2003; 56(10): 747 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Schraml, G. Schwerdtfeger, F. Burkhalter, A. Raggi, D. Schmidt, T. Ruffalo, W. King, K. Wilber, M. J. Mihatsch, and H. Moch Combined Array Comparative Genomic Hybridization and Tissue Microarray Analysis Suggest PAK1 at 11q13.5-q14 as a Critical Oncogene Target in Ovarian Carcinoma Am. J. Pathol., September 1, 2003; 163(3): 985 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Qiuling, Z. Yuxin, Z. Suhua, X. Cheng, L. Shuguang, and H. Fengsheng Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population Carcinogenesis, September 1, 2003; 24(9): 1499 - 1503. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, S. Rodriguez, J. C. Cigudosa, O. Diez, C. Alonso, et al. Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations: Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers Clin. Cancer Res., September 1, 2003; 9(10): 3606 - 3614. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Vrolijk, W. Sloos, W. Mesker, P. Franken, R. Fodde, H. Morreau, and H. Tanke Automated Acquisition of Stained Tissue Microarrays for High-Throughput Evaluation of Molecular Targets J. Mol. Diagn., August 1, 2003; 5(3): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van de Rijn, C. M. Perou, R. Tibshirani, P. Haas, O. Kallioniemi, J. Kononen, J. Torhorst, G. Sauter, M. Zuber, O. R. Kochli, et al. Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome Am. J. Pathol., December 1, 2002; 161(6): 1991 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Merlin, M. Barberi-Heyob, and N. Bachmann In vitro comparative evaluation of trastuzumab (Herceptin(R)) combined with paclitaxel (Taxol(R)) or docetaxel (Taxotere(R)) in HER2-expressing human breast cancer cell lines Ann. Onc., November 1, 2002; 13(11): 1743 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Packeisen, H Buerger, R Krech, and W Boecker Tissue microarrays: a new approach for quality control in immunohistochemistry J. Clin. Pathol., August 1, 2002; 55(8): 613 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mohr, G. D. Leikauf, G. Keith, and B. H. Rihn Microarrays as Cancer Keys: An Array of Possibilities J. Clin. Oncol., July 15, 2002; 20(14): 3165 - 3175. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Andersen, O. Monni, U. Wagner, J. Kononen, M. Barlund, C. Bucher, P. Haas, A. Nocito, H. Bissig, G. Sauter, et al. High-Throughput Copy Number Analysis of 17q23 in 3520 Tissue Specimens by Fluorescence in Situ Hybridization to Tissue Microarrays Am. J. Pathol., July 1, 2002; 161(1): 73 - 79. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shang and M. Brown Molecular Determinants for the Tissue Specificity of SERMs Science, March 29, 2002; 295(5564): 2465 - 2468. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Stojadinovic, R. A. Ghossein, A. Hoos, A. Nissan, D. Marshall, M. Dudas, C. Cordon-Cardo, D. P. Jaques, and M. F. Brennan Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization J. Clin. Oncol., February 15, 2002; 20(4): 941 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoos, A. Stojadinovic, B. Singh, M. E. Dudas, D. H. Y. Leung, A. R. Shaha, J. P. Shah, M. F. Brennan, C. Cordon-Cardo, and R. Ghossein Clinical Significance of Molecular Expression Profiles of Hurthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays Am. J. Pathol., January 1, 2002; 160(1): 175 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, O. R. Kochli, F. Mross, H. Dieterich, H. Moch, M. Mihatsch, et al. Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints Am. J. Pathol., December 1, 2001; 159(6): 2249 - 2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schoenberg Fejzo and D. J. Slamon Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins Am. J. Pathol., November 1, 2001; 159(5): 1645 - 1650. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Oka, T. Yoshino, K. Hayashi, N. Ohara, T. Nakanishi, Y. Yamaai, A. Hiraki, C. A. Sogawa, E. Kondo, N. Teramoto, et al. Reduction of Hematopoietic Cell-Specific Tyrosine Phosphatase SHP-1 Gene Expression in Natural Killer Cell Lymphoma and Various Types of Lymphomas/Leukemias : Combination Analysis with cDNA Expression Array and Tissue Microarray Am. J. Pathol., October 1, 2001; 159(4): 1495 - 1505. [Abstract] [Full Text] |
||||
![]() |
R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, et al. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer J Natl Cancer Inst, August 1, 2001; 93(15): 1141 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Shridhar, J. Lee, A. Pandita, S. Iturria, R. Avula, J. Staub, M. Morrissey, E. Calhoun, A. Sen, K. Kalli, et al. Genetic Analysis of Early- versus Late-Stage Ovarian Tumors Cancer Res., August 1, 2001; 61(15): 5895 - 5904. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Simon, J. Richter, U. Wagner, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. High-Throughput Tissue Microarray Analysis of 3p25 (RAF1) and 8p12 (FGFR1) Copy Number Alterations in Urinary Bladder Cancer Cancer Res., June 1, 2001; 61(11): 4514 - 4519. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Daigo, S.-F. Chin, K. L. Gorringe, L. G. Bobrow, B. A. J. Ponder, P. D. P. Pharoah, and C. Caldas Degenerate Oligonucleotide Primed-Polymerase Chain Reaction-Based Array Comparative Genomic Hybridization for Extensive Amplicon Profiling of Breast Cancers : A New Approach for the Molecular Analysis of Paraffin-Embedded Cancer Tissue Am. J. Pathol., May 1, 2001; 158(5): 1623 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
O.-P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum. Mol. Genet., April 1, 2001; 10(7): 657 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoos, M. J. Urist, A. Stojadinovic, S. Mastorides, M. E. Dudas, D. H. Y. Leung, D. Kuo, M. F. Brennan, J. J. Lewis, and C. Cordon-Cardo Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors Am. J. Pathol., April 1, 2001; 158(4): 1245 - 1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Srivastava, L. Bubendorf, V. Srikantan, L. Fossom, L. Nolan, M. Glasman, X. Leighton, W. Fehrle, S. Pittaluga, M. Raffeld, et al. ANX7, a candidate tumor suppressor gene for prostate cancer PNAS, March 29, 2001; (2001) 71055798. [Abstract] [Full Text] |
||||
![]() |
P. A. Cornford, A. R. Dodson, K. F. Parsons, A. D. Desmond, A. Woolfenden, M. Fordham, J. P. Neoptolemos, Y. Ke, and C. S. Foster Heat Shock Protein Expression Independently Predicts Clinical Outcome in Prostate Cancer Cancer Res., December 1, 2000; 60(24): 7099 - 7105. [Abstract] [Full Text] |
||||
![]() |
K. Oode, T. Furuya, K. Harada, S. Kawauchi, K. Yamamoto, T. Hirano, and K. Sasaki The Development of a Cell Array and Its Combination with Laser-Scanning Cytometry Allows a High-Throughput Analysis of Nuclear DNA Content Am. J. Pathol., September 1, 2000; 157(3): 723 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bubendorf, M. Kolmer, J. Kononen, P. Koivisto, S. Mousses, Y. Chen, E. Mahlamaki, P. Schraml, H. Moch, N. Willi, et al. Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays J Natl Cancer Inst, October 20, 1999; 91(20): 1758 - 1764. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Srivastava, L. Bubendorf, V. Srikantan, L. Fossom, L. Nolan, M. Glasman, X. Leighton, W. Fehrle, S. Pittaluga, M. Raffeld, et al. ANX7, a candidate tumor suppressor gene for prostate cancer PNAS, April 10, 2001; 98(8): 4575 - 4580. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |